High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis

Cancer Research

Volumn 77, Issue 9, 2017, Pages 2464-2475

  Hartmaier, Ryan J ^a   Albacker, Lee A ^a   Chmielecki, Juliann ^a   Bailey, Mark ^a   He, Jie ^a   Goldberg, Michael E ^a   Ramkissoon, Shakti ^a   Suh, James ^a   Elvin, Julia A ^a   Chiacchia, Samuel ^a   Frampton, Garrett M ^a   Ross, Jeffrey S ^a,b   Miller, Vincent ^a   Stephens, Philip J ^a   Lipson, Doron ^a  

^a FOUNDATION MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; NOTCH1 RECEPTOR; PHOSPHOTRANSFERASE; SMAD4 PROTEIN; TUMOR PROTEIN;

ADENOID CYSTIC CARCINOMA; ADULT; ARTICLE; BREAST CANCER; CARCINOGENESIS; COHORT ANALYSIS; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG CANCER; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIPLE CANCER; MUTATION RATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SOLID MALIGNANT NEOPLASM; SPECTROSCOPY; TUMOR CELL; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOMICS; MUTATION; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PRECISION MEDICINE;

EID: 85019027650     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2479     Document Type: Article

References (51)

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
2. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
3. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481-98.
4. Pereira S, Gibbs RA, McGuire AL. Open access data sharing in genomic research. Genes 2014;5:739-47.
5. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
6. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
7. Ettinger DS,WoodDE, Chair Fred V, Aisner DL, Bauman J, Chirieac LR, et al. NCCN Guidelines Version 3.2017 Panel Members Non-Small Cell Lung Cancer-Farber/Brigham and Women'sCancer Center. FortWashington, PA: National Comprehensive Cancer Network; 2016[cited 2016 Nov 21]. Available from: https://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf.
8. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P,Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015;348:124-8.
9. Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 2015;9: 967-96.
10. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ,Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
11. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-31.
12. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011;39: e118.
13. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
14. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487: 330-7.
15. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrentmutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 2016;34:155-63.
16. Fleming NI, Jorissen RN, Mouradov D, ChristieM, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res 2013;73:725-35.
17. Morris LGT, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, et al. The molecular landscape of recurrent and metastatic head and neck cancers. JAMA Oncol. 2016 Jul 21. [Epub ahead of print].
18. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
19. Ho AS, Kannan K, Roy DM, Morris LGT, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013;45:791-8.
20. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013;123:2965-8.
21. Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, et al. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Am J Surg Pathol 2014;38:235-8.
22. Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 2013;6:943-55.
23. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013;122:3169-77.
24. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216-31.
25. Bridge JA, KanamoriM,Ma Z, Pickering D, Hill DA, LydiattW, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-5.
26. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014;111:4233-8.
27. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 1999;84:4232-8.
28. FalchookGS,OrdonezNG,BastidaCC,StephensPJ, MillerVA,GaidoL,et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. J Clin Oncol 2016;34:e141-4.
29. Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer 2016;138:881-90.
30. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res 2013;26:845-51.
31. Ou SH, Chalmers ZR, Azada MC, Ross JS, Stephens PJ, Ali SM, et al. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer 2015; 88:352-4.
32. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosom Cancer 2003;37:58-71.
33. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
34. Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, et al. Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer 2014;53:1033-40.
35. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-91.
36. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 2015;20:7-12.
37. Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, et al. Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing. Clin Cancer Res 2016;22:3281-5.
38. Ye K, Wang J, Jayasinghe R, Lameijer EW, McMichael JF, Ning J, et al. Systematic discovery of complex insertions and deletions in human cancers. Nat Med 2016;22:97-104.
39. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 2016;34:179-85.
40. Tsukuda K, Tanino M, Soga H, Shimizu N, Shimizu K. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 2000;278:653-8.
41. Gremer L,Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, ZenkerM, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 2011;32: 33-43.
42. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013;13:663-73.
43. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371-5.
44. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, et al. Phase II Trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-8.
45. Cadoo KA, Gucalp A, Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer 2014;6: 123-33.
46. Ciznadija D, Liu Y, Pyonteck SM, Holland EC, Koff A. Cyclin D1 and Cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res 2011;71:6174-83.
47. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastomawith amesenchymal-epithelial transition inhibitor. J Clin Oncol 2012;30:e30-3.
48. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17Kmutation incommon solid cancers and acute leukaemias. Br J Cancer 2008;98:1533-5.
49. Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C, et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol 2016; 69:767-71.
50. Hechtman JF, Sadowska J, Huse JT, Borsu L, Yaeger R, Shia J, et al. AKT1 E17K in colorectal carcinoma is associated with BRAF V600E but not MSI-H status: a clinicopathologic comparison to PIK3CA helical and kinase domain mutants. Mol Cancer Res 2015;13:1003-8.
51. Ledermann J, Harter P, Gourley C, FriedlanderM, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.